Brinton Pharmaceuticals receives Series B funding from India Alternatives

India Alternatives Investment Advisors Ltd. has invested up to USD 8 million for a significant minority stake in Brinton Pharmaceuticals Limited. Among the fastest-growing companies in the Indian pharmaceutical market, Brinton is focused on dermatology and has recently expanded into the pediatric dermatology and respiratory segments. This transaction marks the second investment in Brinton by an institutional investor, following Tata Capital Healthcare Fund’s investment in 2017.

Share this:

Related Post

Stay Updated on Medical Equipment and Devices industry.
Receive our Daily Newsletter.